NCT02514252 2021-05-18
Sublingual Fentanyl for the Management of Breakthrough Pain
M.D. Anderson Cancer Center
Phase 2 Terminated
M.D. Anderson Cancer Center
University of Wisconsin, Madison
McGill University Health Centre/Research Institute of the McGill University Health Centre
gicare Pharma Inc.